Severe acute respiratory syndrome (SARS), which is caused by a newly identified human coronavirus named SARS-associated coronavirus (SARS-CoV), killed more than 800 people and posed significant challenges for the public health systems and hospital workers during the outbreak in 2002--2003. SARS may still remain a threat to the public health since the natural reservoir of SARS-CoV remains largely unknown and there are no specific treatments and effective vaccines available for SARS-CoV infection. To further identify molecular targets for the development of novel strategies against SARS-CoV infection, we have employed siRNA mediated RNA interference technology to examine the potential effects of a panel of siRNA molecules on the viral entry and/or replication of SARS-CoV by targeting the genes encoding the human angiotensin-converting enzyme 2 (ACE2) receptor or the viral nucleocapsid protein (NP). We first found that some of the siRNA duplexes that were treated by Yan Xin Life Science and Technology (YXLST) could dramatically and specifically down-regulate the cellular ACE2 receptor or viral NP expression in a dose-dependent manner in human 293T cells. We then showed that the siRNA directed against ACE2 receptor could potently suppress the viral entry of the spike protein pseudotyped viruses. We further demonstrated that these siRNA molecules targeting ACE2 or NP genes could also markedly suppress the cytopathic effect (CPE) of the SARS-CoV infected cells, and potently inhibit the viral replication. Therefore, our study has identified two highly conserved molecular targets for the siRNA-mediated RNA interference against SARS-CoV infection.
